AstraZeneca PLC (AZN)
| Market Cap | 265.22B +15.6% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.39 |
| Forward PE | 15.98 |
| Dividend | $3.23 (1.90%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 1,094,911 |
| Open | 170.53 |
| Previous Close | 171.34 |
| Day's Range | 168.44 - 170.74 |
| 52-Week Range | 141.77 - 212.71 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 213.69 (+25.42%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $213.69, which is an increase of 25.42% from the latest price.
News
AZN Looks 4.9% Undervalued on GF Value⢠After EU Approval for Datroway
AZN Looks 4.9% Undervalued on GF Value⢠After EU Approval for Datroway
AZN Looks 4.9% Undervalued on GF Value⢠After EU Approval Boost
AZN Looks 4.9% Undervalued on GF Value⢠After EU Approval Boost
AstraZeneca, Daiichi Sankyo’s Datroway approved in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Datroway has been approved in the European Union, EU, as monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic triple-...
A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors
Investors are becoming more open to international equities after years of U.S.-heavy portfolios, Janus Henderson Investors' Julian McManus told CNBC. McManus said "Magnificent Seven" concentration has...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to con...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders “A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gi...
AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales
AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales
Mercedes China-Dämpfer, Applied Digital Rekord, Celestica stark
In der heutigen Sendung geht es um diese Werte: TeamViewer, K+S, Mercedes-Benz, Unilever, AstraZeneca, Baker Hughes, Amkor, Navitas Semiconductor, Applied Digital und Celestica.
The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS
AAPL, MSFT and AMZN earnings join key central bank meetings as investors track AI spending, interest rates and rising geopolitical risks.
AstraZeneca's Sone-Ve Improves Survival In Gastric Cancer Trial
(RTTNews) - AstraZeneca (AZN) and Keymed Biosciences (2162.HK), through their joint venture with Lepu Biopharma, announced that the antibody drug conjugate Sonesitatug vedotin (Sone-Ve) demonstrated a...
AstraZeneca shares soar amid strong demand for cancer treatments
Revenues for the first half rose 6% to £23bn while profits rose 2% to £5bn. Chief exec Pascal Soriot, pictured, pointed to booming sales of specific canc
AstraZeneca (AZN) Reports Strong Q2 Earnings, Reaffirms $80 Billion Revenue Goal
AstraZeneca (AZN) Reports Strong Q2 Earnings, Reaffirms $80 Billion Revenue Goal
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
AstraZeneca (AZN) Reports Strong Q2 Earnings and Raises Dividend
AstraZeneca (AZN) Reports Strong Q2 Earnings and Raises Dividend
AstraZeneca's Sone-Ve (AZN) Shows Promising Results in Late-Stage Gastric Cancer Trial
AstraZeneca's Sone-Ve (AZN) Shows Promising Results in Late-Stage Gastric Cancer Trial
AstraZeneca boss says AI won't replace many jobs at his firm... but will make workers 'smarter and faster'
Pascal Soriot, the chief executive of one of Britain's biggest companies, said that he does not expect a 'big reduction' in jobs at his group due to AI.
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopat...
Omeros up 11% to $10.89 after AstraZeneca study failure
10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure
Astrazeneca Q2 Earnings Call Highlights
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per sha...
AstraZeneca drug prices evolving in response to Trump policy, executive says
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a s...
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed'
Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot
AstraZeneca (AZN) Increases Interim Dividend to $1.06 Per Share
AstraZeneca (AZN) Increases Interim Dividend to $1.06 Per Share
AstraZeneca (AZN) Aims for $80 Billion Revenue by 2030
AstraZeneca (AZN) Aims for $80 Billion Revenue by 2030